Cure :: Red mushroom a cure for ailments

Red mushroom, the ancient Chinese secret of health and longevity, is emerging as an elixir of life for many in India suffering from various ailments, including cancer, claim doctors in Tamil Nadu and Kerala.

Psoriasis :: Glucocorticoid plays key role in skin abnormalities induced by psychological stress

A new study shows how psychological stress induces abnormalities in skin structure and function that could initiate or worsen skin disorders such as psoriasis and atopic dermatitis. The study provides a link for understanding the roles psychological stress and glucocorticoid, a type of steroid, play in skin disorders and shows that blocking glucocorticoid can prevent skin abnormalities induced by psychological stress.

Hepatitis :: PEG-INTRON, peginterferon and REBETOL, ribavirin in Hepatitis C — Schering-Plough

Schering-Plough reported data from EPIC3, a large ongoing clinical study, showing that retreatment with PEG-INTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy can result in sustained virologic response(1) (SVR) in patients with chronic hepatitis C who failed previous treatment with any alpha interferon-based combination therapy, including peginterferon regimens. In this study, 56 percent of patients who had undetectable virus (HCV-RNA) after 12 weeks went on to achieve SVR with a 48-week course of therapy. Of the first 1,354 patients retreated, approximately 38 percent had undetectable virus at week 12. Importantly, patients who did not have undetectable virus at 12 weeks had little chance of achieving SVR. Overall, 23 percent of patients achieved SVR.

Inflammatory Disease :: Array BioPharma’s MEK Inhibitor, ARRY-438162, meets initial clinical objectives

Array BioPharma Inc. (Nasdaq: ARRY) announced that its first-in-class MEK inhibitor for the treatment of inflammatory diseases, ARRY-438162, has met its primary objectives in a single ascending dose clinical study involving 20 healthy volunteers. These results were presented by Array?s President and Chief Scientific Officer, Kevin Koch, Ph.D., at the 14th International Inflammation Research Association Conference in Cambridge, Maryland.

Obesity :: Manhattan pharmaceuticals – oral oleoyl-estrone clinical program to include morbidly obese

Manhattan Pharmaceuticals, Inc. (Amex: MHA) today announced expansion of its oral Oleoyl-estrone (OE) clinical obesity program to include the morbidly obese. A new US Phase 2a clinical trial evaluating oral OE in morbidly obese male subjects will be initiated in October 2006. The morbidly obese population in the US is estimated to be 14 million people. OE is the Company’s orally administered product candidate in development for the treatment of obesity.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack